UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy
Broadens Epilepsy Portfolio With $1.9bn Purchase
Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.
